GSK Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:GSK Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
30 Oct 24	BuyUK£99,646	Jonathan Symonds	Individual	7,150	UK£13.94
20 Jun 24	BuyUK£32,291	Jonathan Symonds	Individual	2,000	UK£16.15
20 Jun 24	BuyUK£7,196	Wendy Mira Becker	Individual	446	UK£16.14
01 Feb 24	BuyUK£54,972	Jonathan Symonds	Individual	3,500	UK£15.71
01 Feb 24	BuyUK£306,430	Julie Brown	Individual	19,360	UK£15.83

Insider Trading Volume

Insider Buying: GSK insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GSK?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	1,513,610	0.0371%
Individual Insiders	3,462,794	0.0849%
State or Government	6,721,309	0.165%
Private Companies	45,212,040	1.11%
Employee Share Scheme	72,705,245	1.78%
General Public	450,091,533	11%
Institutions	3,500,793,170	85.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 50.95% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.1%	Dodge & Cox	371,510,592	UK£4.9b	-0.07%	2.09%
8.59%	BlackRock, Inc.	350,659,869	UK£4.6b	3.36%	0.09%
4.71%	The Vanguard Group, Inc.	192,238,225	UK£2.5b	-0.26%	0.05%
2.24%	State Street Global Advisors, Inc.	91,452,659	UK£1.2b	0.42%	0.06%
2.08%	Wellington Management Group LLP	84,761,803	UK£1.1b	6.08%	0.22%
2.05%	FMR LLC	83,626,841	UK£1.1b	-8.05%	0.08%
1.95%	Legal & General Investment Management Limited	79,559,851	UK£1.1b	-2.84%	0.23%
1.87%	Norges Bank Investment Management	76,353,487	UK£1.0b	-2.97%	0.1%
1.78%	GlaxoSmithKline Employee Trust	72,705,245	UK£959.7m	-0.19%	no data
1.72%	UBS Asset Management AG	70,132,864	UK£925.8m	-5.2%	0.11%
1.69%	Schroder Investment Management Limited	69,010,834	UK£910.9m	-14.3%	0.72%
1.32%	HSBC Global Asset Management (UK) Limited	53,941,563	UK£712.0m	30.4%	0.35%
1.25%	Mondrian Investment Partners Limited	51,161,344	UK£675.3m	10.2%	5.74%
1.2%	Silchester International Investors LLP	49,126,050	UK£648.5m	0%	3.16%
1.11%	GlaxoSmithKline plc, Shareview Client	45,212,040	UK£596.8m	-2.21%	no data
1.01%	Royal Bank of Canada Trust Company (Bahamas) Limited, Asset Management Arm	41,054,236	UK£541.9m	-1.91%	17.54%
0.99%	Fisher Asset Management, LLC	40,570,368	UK£535.5m	0.13%	0.27%
0.98%	Aviva Investors Global Services Ltd.	39,860,069	UK£526.2m	-0.39%	0.88%
0.83%	Strategic Advisers LLC	34,050,387	UK£449.5m	12.3%	0.21%
0.82%	Columbia Management Investment Advisers, LLC	33,429,674	UK£441.3m	1.46%	0.12%
0.78%	Royal London Asset Management Ltd.	31,987,291	UK£422.2m	5.88%	0.67%
0.73%	Causeway Capital Management LLC	29,934,107	UK£395.1m	32.7%	2.03%
0.73%	PRIMECAP Management Company	29,707,510	UK£392.1m	2.36%	0.36%
0.72%	Franklin Resources, Inc.	29,365,607	UK£387.6m	-1.79%	0.17%
0.67%	Amundi Asset Management SAS	27,482,669	UK£362.8m	-1.85%	0.09%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 08:21
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GSK plc is covered by 63 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research